Literature DB >> 18661337

Role of emmprin/CD147 in tissue remodeling.

Eric Huet1, Eric E Gabison, Samia Mourah, Suzanne Menashi.   

Abstract

Emmprin/CD147 is a cell membrane glycoprotein that belongs to the Ig superfamily and is involved in numerous physiological and pathological systems. Through its ability to interact with multiple partners within the cell surface and its potential to regulate the expression of several targets within the cell, emmprin may have different functions depending on the cell or tissue type. However, its role in tissue remodeling remains the most clearly demonstrated. Emmprin is able to induce, in the same cellular model, both the matrix metalloproteinases and the serine protease urokinase plasminogen activator, whose concerted action in the breakdown of the extracellular matrix (ECM) during various physiopathological situations has been reported. In addition, emmprin also promotes myofibroblasts' differentiation and tissue contraction through the induction of alpha smooth muscle actin, thus expanding on the mechanism by which emmprin remodels ECM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18661337     DOI: 10.1080/03008200802151722

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  26 in total

1.  EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling.

Authors:  Balachandar Venkatesan; Anthony J Valente; Sumanth D Prabhu; Prakashsrinivasan Shanmugam; Patrice Delafontaine; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2010-06-09       Impact factor: 5.000

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

4.  EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.

Authors:  S Sangboonruang; P Thammasit; N Intasai; W Kasinrerk; C Tayapiwatana; K Tragoolpua
Journal:  Cancer Gene Ther       Date:  2014-06-13       Impact factor: 5.987

Review 5.  Clathrin-independent endocytosis: a cargo-centric view.

Authors:  Lymarie Maldonado-Báez; Chad Williamson; Julie G Donaldson
Journal:  Exp Cell Res       Date:  2013-08-13       Impact factor: 3.905

6.  EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone.

Authors:  Yiping Dang; Wei Li; Victoria Tran; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-07-13       Impact factor: 5.858

7.  EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease.

Authors:  Eric Huet; Benoit Vallée; Jean Delbé; Samia Mourah; Virginie Prulière-Escabasse; Magali Tremouilleres; Kenji Kadomatsu; Serge Doan; Christophe Baudouin; Suzanne Menashi; Eric E Gabison
Journal:  Am J Pathol       Date:  2011-07-21       Impact factor: 4.307

Review 8.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

9.  EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.

Authors:  Faten Bougatef; Suzanne Menashi; Farah Khayati; Benyoussef Naïmi; Raphaël Porcher; Marie-Pierre Podgorniak; Guy Millot; Anne Janin; Fabien Calvo; Céleste Lebbé; Samia Mourah
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

10.  Molecular determinants of microvascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Wentao Yu; Wei Gao; Dan Rong; Zhixian Wu; Raouf A Khalil
Journal:  Microcirculation       Date:  2018-10-19       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.